Loading...
Cordycepin Reverses Cisplatin Resistance in Non-small Cell Lung Cancer by Activating AMPK and Inhibiting AKT Signaling Pathway
Cisplatin (DDP) is the first-line chemotherapeutic agent against lung cancer. However, the therapeutic effect of DDP loses over time due to the acquired drug resistance in non-small cell lung cancer (NSCLC) cells. In recent years, the role of the traditional Chinese medicine (TCM) cordycepin (Cor) i...
Na minha lista:
| Udgivet i: | Front Cell Dev Biol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7843937/ https://ncbi.nlm.nih.gov/pubmed/33520990 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2020.609285 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|